Al­ler­gan picks up op­tion for Ed­i­tas' rare eye dis­ease drug; Cure­Ge­net­ics bags $17M

→ Al­ler­gan has stepped in to pick up its de­vel­op­ment op­tion on Ed­i­tas‘ ex­per­i­men­tal ED­IT-101 for Leber con­gen­i­tal amau­ro­sis type 10. And the small­er biotech is grab­bing co-pro­mo­tion rights as they look to a fu­ture ex­pan­sion in­to com­mer­cial op­er­a­tions. Ed­i­tas gets $15 mil­lion up­front with an­oth­er $25 mil­lion due on the IND.

→ Chi­na gene-edit­ing biotech Cure­Ge­net­ics has round­ed up a $17 mil­lion round to back its de­vel­op­ment. Qim­ing Ven­ture Part­ners led the round with ad­di­tion­al in­vestors which in­clud­ed CTS Cap­i­tal and As­cendin In­vest­ment. The com­pa­ny plans to use the mon­ey on an IND and pipeline de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.